The new therapeutic dilemma in pediatrics

Cutis

Volumn 75, Issue 4, 2005, Pages 205-206

  Silverberg, Nanette B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; PIMECROLIMUS; TSUKUBAENOLIDE;

ATOPIC DERMATITIS; CANCER RISK; DRUG BLOOD LEVEL; DRUG SAFETY; EDITORIAL; FEAR; GROWTH INHIBITION; HERPES SIMPLEX; HUMAN; LYMPHOMA; MALNUTRITION; MEDICAL INFORMATION; MEDICAL SOCIETY; PEDIATRICS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER;

CALCINEURIN; CHILD; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; TACROLIMUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 18244409653     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. US Food and Drug Administration. Pediatric Advisory Subcommittee to the Anti-Infective Drugs Advisory Committee. open meeting. October 29-30, 2003. Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3999B1_02_cover%20Memo. doc. Accessed March 20, 2005.
2. US Food and Drug Administration. Elidel and Protopic drug review. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm. Accessed February 16, 2005.
3. Mathews AW, Abboud L. New FDA board. Wall Street Journal. February 16, 2005:A1, A6.
4. US Food and Drug Administration. FDA Talk Paper: FDA Issues Public Health Advisory Informing Health Care Providers of Safety Concerns Associated With the Use of Two Eczema Drugs, Elidel and Protopic. Rockville, MD: FDA Office of Public Affairs; March 10, 2005. Talk Paper T05-06.
5. Wollenberg A, Wetzel S, Burgdorf WH, et al. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol. 2003;112:667-674.
6. Hill B. Topical immunosuppressants (calcineurin inhibitors) - animal toxicology. Available at: www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4089s2_01_06_Hill.ppt. Accessed March 20, 2005.
7. Krafchik BR, Halbert A, Yamamoto K, et al. Atopic dermatitis. In: Schachner LA, Hansen RC, eds. Pediatric Dermatology. 3rd ed. Philadelphia, Pa: Mosby; 2003:609-630.
8. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2.
9. Enke BU, Bokenkamp A, Offner G, et al. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation. 1997;64:237-241.
10. US Food and Drug Administration. Tacrolimus topical. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm. Accessed February 16, 2005.
11. Temeck J, for the Division of Pediatric Drug Development. Protopic and Elidel presentation for regulatory briefing on January 14, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2_01_02_DPDD%20Consult.pdf. Accessed March 20, 2005.
12. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon school children. J Am Acad Dermatol. 2000;43:649-655.